Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04535713
Title Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Sarcoma Oncology Research Center, LLC
Indications

sarcoma

Therapies

Docetaxel + Doxorubicin + Gemcitabine + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.